arrow
F

Fiona Taylor

adelphi values
H指数:36
被引数:8,436

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial

在随机III期CheckMate 76 K试验中,接受完全切除的IIB/C期黑色素瘤患者使用辅助纳武利尤单抗 versus 安慰剂治疗后的患者报告结局。

2025-05-010
OAAI
Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
2024-06-010
PRE
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

一线nivolumab联合ipilimumab两周期化疗与单纯化疗 (四个周期) 治疗转移性非小细胞肺癌: CheckMate 9LA 2年患者报告的结果

2023-04-019
OAAI
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

Nivolumab联合ipilimumab与化疗作为具有高肿瘤突变负担的晚期非小细胞肺癌的一线治疗: 患者报告的结果来自随机,开放标签,III期CheckMate 227试验的结果

2019-07-01172
OAAI
Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057

在CheckMate 057中评估接受nivolumab或多西他赛治疗的晚期非鳞状非小细胞肺癌患者的健康相关生活质量和症状

2018-10-0163
PREAI